Clinical Trial Update: Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection [Phase 3]

View source ↗

Summary

Phase 3 trial of a Clostridium difficile toxoid vaccine in at-risk subjects was terminated, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• Candidate Clostridium Difficile Toxoid Vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Clostridium Difficile Infection | Phase 3 | Status: TERMINATED | Results posted: 2019-07-05